Abstract: A fan-out semiconductor device includes stacked semiconductor dies having die bond pads arranged in columns exposed at a sidewall of the stacked semiconductor dies. The stacked dies are encapsulated in a photo imageable dielectric (PID) material, which is developed to form through-hole cavities that expose the columns of bond pads of each die at the sidewall. The through-hole cavities are plated or filled with an electrical conductor to form conductive through-holes coupling die bond pads within the columns to each other.

Abstract: Provided are a road safety assessment method and apparatus, and an electronic device and a readable medium. The method comprises: acquiring real-time water level data in a culvert and real-time roadbed state data of a road within a preset distance range from the culvert (S201); on the basis of the roadbed state data, determining anti-pressure capability data of the road (S202); and on the basis of the water level data and the anti-pressure capability data, assessing the safety of the road to obtain a road safety assessment result (S203). The accuracy of road safety assessment is improved, and unattended monitoring without interruption can be realized.

Abstract: The present disclosure provides methods of correcting gene variants associated with Parkinson's Disease in pluripotent stem cells, and methods of lineage specific differentiation of such corrected pluripotent stem cells into floor plate midbrain progenitor cells, determined dopamine (DA) neuron progenitor cells, and/or DA neurons, or into glial cells, such as microglial cells, astrocytes, oligodendrocytes, or ependymocytes. Also provided are compositions uses thereof, such as for treating neurodegenerative diseases and conditions, including Parkinson's disease.

Abstract: The present disclosure provides transposon-based methods of genetic editing in pluripotent stem cells, and methods of lineage specific differentiation of such edited pluripotent stem cells into floor plate midbrain progenitor cells, determined dopamine (DA) neuron progenitor cells, and/or DA neurons, or into glial cells, such as microglial cells, astrocytes, oligodendrocytes, or ependymocytes. Also provided are compositions and uses thereof, such as for treating neurodegenerative diseases and conditions, including Parkinson's disease.

Abstract: Apparatus for use in electronic equipment includes a cap of nonconductive material positioned to collect and retain metallic particles produced by installation of metallic fasteners during assembly of the electronic equipment.

Abstract: Orally administerable deferasirox formulations are disclosed having reduced release under gastric conditions and fast release at near neutral pH or at neutral pH.

Abstract: Orally administerable deferasirox formulations are disclosed having reduced release under gastric conditions and fast release at near neutral pH or at neutral pH.

Abstract: Orally administerable deferasirox formulations are disclosed having reduced release under gastric conditions and fast release at near neutral pH or at neutral pH.

Abstract: Orally administerable deferasirox formulations are disclosed having reduced release under gastric conditions and fast release at near neutral pH or at neutral pH.

Abstract: Orally administerable deferasirox formulations are disclosed having reduced release under gastric conditions and fast release at near neutral pH or at neutral pH.

Abstract: Orally administerable deferasirox formulations are disclosed having reduced release under gastric conditions and fast release at near neutral pH or at neutral pH.

Abstract: The invention provides a formulation of one or more antineoplastic drugs encapsulated in liposomes including at least a lipid fraction in addition to the antineoplastic drug, wherein the composition is stable in an aqueous solution at room temperature.

Abstract: A housing (100, 300, 600, 700) for storing and protecting items comprises a photoreactive material (106) that selectively and irreversibly changes colors upon exposure to activating radiation (124, 324); and an ultraviolet attenuation coating (102, 702) disposed over the photoreactive material (106). Radiation (124, 324) is selectively applied to the photoreactive material (106) to irreversibly change the color of the photoreactive material (106) and therefore the housing (100, 300, 600, 700). An optional patterned layer (332) may be disposed between the photoreactive material (106) and the selective application of radiation (124, 324), and a background color (108) may be included, to affect the visual presentation of the housing (100, 300, 600, 700).

Abstract: The present invention relates to pharmaceutical compositions comprising a topoisomerase I inhibitor including, but not limited to, a camptothecin derivative.

Abstract: A housing (100, 300, 600, 700) for storing and protecting items comprises a photoreactive material (106) that selectively and irreversibly changes colors upon exposure to activating radiation (124, 324); and an ultraviolet attenuation coating (102, 702) disposed over the photoreactive material (106). Radiation (124, 324) is selectively applied to the photoreactive material (106) to irreversibly change the color of the photoreactive material (106) and therefore the housing (100, 300, 600, 700). An optional patterned layer (332) may be disposed between the photoreactive material (106) and the selective application of radiation (124, 324), and a background color (108) may be included, to affect the visual presentation of the housing (100, 300, 600, 700).

Abstract: A method of liposome-based therapy for a mammalian subject is disclosed. The method uses liposomes and/or liposomes with outer surfaces that contain an affinity moiety effective to bind specifically to a biological surface at which the therapy is aimed, and a hydrophilic polymer coating. The hydrophilic polymer coating is made up of polymer chains covalently linked to surface lipid components. After a desired liposome biodistribution is achieved, the affinity agent binds to the target surface and helps internalize the liposomes.

Abstract: The present invention is for novel compositions and methods for treating diseases caused by cellular proliferation, particularly, for treating cancer in mammals and more particularly in humans. The therapeutic compositions of the present invention include SN-38 lipid complexes in which the complexes can contain any of a variety of neutral or charged lipids and, desirably, cardiolipin. The compositions are capable of efficiently incorporating SN-38 into complexes and are capable of solubilizing relatively high concentrations of SN-38.

Abstract: A method of fabricating a nanotube structure which includes providing a substrate, providing a mask region positioned on the substrate, patterning and etching through the mask region to form at least one trench, depositing a conductive material layer within the at least one trench, depositing a solvent based nanoparticle catalyst onto the conductive material layer within the at least one trench, removing the mask region and subsequent layers grown thereon using a lift-off process, and forming at least one nanotube electrically connected to the conductive material layer using chemical vapor deposition with a methane precursor.

Abstract: A method of fabricating a nanotube structure which includes providing a substrate, providing a mask region positioned on the substrate, patterning and etching through the mask region to form at least one trench, depositing a conductive material layer within the at least one trench, depositing a solvent based nanoparticle catalyst onto the conductive material layer within the at least one trench, removing the mask region and subsequent layers grown thereon using a lift-off process, and forming at least one nanotube electrically connected to the conductive material layer using chemical vapor deposition with a methane precursor.

Abstract: Delivering therapeutic amounts of irinotecan remains limited due to its highly water insoluble properties. This invention overcomes this limitation by presenting a novel method of preparing liposomal irinotecan by first inactivating irinotecan prior to liposome formation and then subsequently activating the irinotecan by lowering the pH of the lipid composition to an acidic pH of less than about 3.5, such as between 1.5-3.0 or about 2.